# Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

> **NCT00636909** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 25 (actual)

## Conditions studied

- AML
- ALL
- CML Chronic Phase, Accelerated Phase, or Blast Crisis
- CLL
- MDS
- RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA
- APLASTIC ANEMIA
- MULTIPLE MYELOMA
- MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** fludarabine
- **DRUG:** cyclosporine
- **DRUG:** methotrexate
- **BIOLOGICAL:** G-CSF

## Key facts

- **NCT ID:** NCT00636909
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636909, "Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00636909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*